Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions, consumer healthcare environments, and eye health management settings in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-empowered retina-based auxiliary diagnosis product; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia and retinal detachment; and glaucoma, cataracts, ICVD and ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial hypertension retinopathy, and anemia SaMDs. The company also provides health risk assessment solutions to detect risk indicators, such as retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular diseases, and anemia to various healthcare providers, including health checkup centers, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices comprising AI-FUNDUSCAMERA-P, a portable, automatic, and self-service fundus camera that can easily apply to any healthcare environments; AI-FUNDUSCAMERA-D, a fully automatic and fully self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner integrated with more biosensors to capture retinal images and obtain other physiological data. Further, the company is developing AI-empowered myopia prevention and control, and AI-based visual training products. Additionally, it engages in sale of hardware devices; and provision of AI-based software solutions. The company was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.